Median progression-free survival was 224 months ( 95 % CI 190-252 ) in the group assigned to chlorambucil plus ofatumumab compared with 131 months ( 106-138 ) in the group assigned to chlorambucil only ( hazard ratio 057 , 95 % CI 045-072 ; p < 00001 ) .